Drug Profile
Research programme: protein kinase C-delta inhibitor therapeutics - SpinCo
Alternative Names: PKCd inhibitors - BriaCell TherapeuticsLatest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator BriaCell Therapeutics Corp; Sapientia Pharmaceuticals
- Developer BriaCell Therapeutics Corp
- Class Antifibrotics; Antineoplastics; Skin disorder therapies; Small molecules
- Mechanism of Action Protein kinase C delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- No development reported Systemic scleroderma
Most Recent Events
- 31 Aug 2023 BriaCell Therapeutics closes plan of arrangement spinout transaction to BriaPro Therapeutics (SpinCo) for protein kinase C delta inhibitors
- 25 May 2023 Preclinical development in Cancer is ongoing in USA
- 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in USA